11.96
Elanco Animal Health Inc stock is traded at $11.96, with a volume of 8.52M.
It is down -2.61% in the last 24 hours and up +27.51% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$12.28
Open:
$12.22
24h Volume:
8.52M
Relative Volume:
1.59
Market Cap:
$4.84B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
29.90
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+22.67%
1M Performance:
+27.51%
6M Performance:
-15.00%
1Y Performance:
-30.47%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ELAN
Elanco Animal Health Inc
|
11.96 | 4.84B | 4.45B | 205.00M | 372.00M | 0.40 |
![]()
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-24 | Initiated | UBS | Buy |
Dec-02-24 | Initiated | Leerink Partners | Market Perform |
Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-05-24 | Upgrade | Stifel | Hold → Buy |
Dec-19-23 | Initiated | Jefferies | Buy |
Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-21-22 | Downgrade | Goldman | Buy → Sell |
Jul-12-22 | Initiated | Piper Sandler | Neutral |
Nov-18-21 | Initiated | Morgan Stanley | Overweight |
Oct-28-21 | Downgrade | Stifel | Buy → Hold |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
Apr-15-21 | Initiated | Stifel | Buy |
Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-09-20 | Downgrade | Argus | Buy → Hold |
Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-13-20 | Resumed | Credit Suisse | Neutral |
Aug-04-20 | Resumed | Goldman | Buy |
Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-10-20 | Initiated | Raymond James | Mkt Perform |
Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-23-19 | Initiated | Barclays | Overweight |
Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Aug-15-19 | Upgrade | UBS | Sell → Neutral |
May-23-19 | Initiated | Guggenheim | Neutral |
Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
Feb-12-19 | Initiated | William Blair | Mkt Perform |
Jan-23-19 | Initiated | UBS | Sell |
Jan-15-19 | Initiated | Argus | Buy |
Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Q2 EPS Estimate for Elanco Animal Health Reduced by Analyst - Defense World
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2025 Earnings Call Transcript - Insider Monkey
Stifel raises Elanco stock price target to $15 from $13 - Investing.com
Elanco Animal Health (ELAN) Stock Price Target Raised by Stifel | ELAN Stock News - GuruFocus
Elanco (ELAN) Stock Target Raised by Stifel Following Strong Quarter | ELAN Stock News - GuruFocus
Elanco Animal Health First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Elanco Animal Health (NYSE:ELAN) Shares Gap Up Following Strong Earnings - Defense World
Elanco Animal Health Inc (ELAN) Q1 2025 Earnings Call Highlights: Strong Innovation Revenue and ... - Yahoo Finance
Elanco Animal Health Inc (ELAN) Q1 2025 Earnings Call Highlights: Strong Innovation Revenue and Raised Full-Year Guidance Amid Retail Challenges - GuruFocus
Why Elanco Animal Health Incorporated (ELAN) Skyrocketed On Wednesday - Insider Monkey
Decoding Elanco Animal Health Inc (ELAN): A Strategic SWOT Insig - GuruFocus
Health Care Stocks Climb As Companies Show Strong Gains - Finimize
Elanco Animal Health Shares Rise After Q1 Beat - marketscreener.com
Elanco (ELAN) Stock Target Raised by Analyst Amid Favorable Quarter | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Sees Strong Q1 Performance and Raises Outlook - GuruFocus
Elanco (ELAN) Stock Trades Up, Here Is Why - Yahoo Finance
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide - Benzinga
Elanco Animal Health (ELAN) Raises Full-Year Revenue Outlook - GuruFocus
Transcript : Elanco Animal Health Incorporated, Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Elanco Animal Health Inc SEC 10-Q Report - TradingView
Elanco stock spikes after Q1 beat (ELAN:NYSE) - Seeking Alpha
Elanco Animal Health Beats Q1 Estimates, Faces Revenue Growth ChallengesNews and Statistics - IndexBox
Elanco (ELAN) Beats Earnings Estimates, Raises 2025 Revenue Guidance - GuruFocus
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Elanco Q1 2025 slides: Revenue guidance raised amid innovation-driven growth - Investing.com Canada
Elanco Animal Health beats Q1 estimates, shares rise over 3% By Investing.com - Investing.com South Africa
Elanco Animal Health beats Q1 estimates, shares rise over 3% - Investing.com
Elanco (ELAN) Revises 2025 Revenue Forecast and Affirms Profit Projections | ELAN Stock News - GuruFocus
Elanco Animal Health Inc (ELAN) Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Revenue at $1,193 Million Surpasses Expectations - GuruFocus
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Elanco (ELAN) Reports Strong Q1 Revenue with Raised 2025 Guidance | ELAN Stock News - GuruFocus
Elanco Animal Health Reports First Quarter 2025 Results | ELAN Stock News - GuruFocus
Elanco Animal Health Reports First Quarter 2025 Results - TradingView
Elanco Animal Health Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by First Trust Advisors LP - Defense World
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL.com
Companion Animal Vaccine Market Is Booming So Rapidly 2025-2032 - openPR.com
Elanco (ELAN) Reports Q1: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Yahoo Finance
Commit To Buy Elanco Animal Health At $8, Earn 13.1% Using Options - Nasdaq
Elanco Sells Xdemvy Royalty, Milestone Rights to Blackstone Affiliates for $295 Million - marketscreener.com
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human - GuruFocus
Elanco Sells Royalty, Milestone Rights For Lotilaner In Human Health To Blackstone For $295 Mln Cash - Nasdaq
Elanco Sells Royalty And Milestone Rights For Lotilaner In Human Health To Blackstone Accelerates Debt Paydown - marketscreener.com
Elanco Cuts Debt With $295M Blackstone Deal: Key Details on Leverage Target and XDEMVY Royalty Sale - Stock Titan
Analyzing Ratios: Elanco Animal Health Inc (ELAN)’s Financial Story Unveiled - DWinneX
Renaissance Technologies LLC Has $760,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Cyromazine Market Deep Research Report with Forecast by 2032 | - openPR.com
Elanco Animal Health Inc [ELAN] Shares Fall Approximately -28.51% Over the Year - knoxdaily.com
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline - Yahoo Finance
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):